Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 4/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL555438 | 0.85 | ALDH1A1 (0.49) | TAAR1POLBKMT2ACA12CA1 | |
| SCHEMBL24242025 | 0.84 | P2RX7 (0.54) | KMT2AALDH1A1HSD17B10 | |
| SCHEMBL33530786 | 0.83 | TAAR1 (0.56) | TAAR1CA12CA1CA2CA9 | |
| SCHEMBL12851863 | 0.83 | TAAR1 (0.56) | TAAR1POLBKMT2ACA12CA1 | |
| SCHEMBL2795606 | 0.81 | SPR (0.49) | SPRLMNAPOLBKMT2AALDH1A1 | |
| SCHEMBL2795344 | 0.80 | MTNR1A (0.49) | SPRPOLBKMT2AMTNR1AMTNR1B | |
| SCHEMBL533866 | 0.79 | MTNR1A (0.61) | TAAR1LMNAKMT2AMTNR1AMTNR1B | |
| SCHEMBL29686650 | 0.79 | MTNR1A (0.61) | TAAR1LMNAKMT2AMTNR1AMTNR1B | |
| SCHEMBL6956890 | 0.78 | SPR (0.70) | SPRTAAR1LMNAMAPK1ALDH1A1 | |
| SCHEMBL3638162 | 0.77 | TAAR1 (0.56) | TAAR1LMNAPOLBKMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | SPR 3392/4885TAAR1 1518/4885LMNA 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.